Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) rose 5% during trading on Tuesday after TD Cowen raised their price target on the stock from $73.00 to $78.00. TD Cowen currently has a buy rating on the stock. Vera Therapeutics traded as high as $42.72 and last traded at $42.1470. 404,335 shares were traded during mid-day trading, a decline of 68% from the average session volume of 1,266,493 shares. The stock had previously closed at $40.13.
Several other research analysts have also issued reports on the stock. Wedbush raised their price target on shares of Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a report on Wednesday. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a research report on Friday, May 15th. HC Wainwright lifted their target price on shares of Vera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Guggenheim boosted their target price on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.58.
View Our Latest Analysis on Vera Therapeutics
Insider Buying and Selling
Vera Therapeutics News Roundup
Here are the key news stories impacting Vera Therapeutics this week:
- Positive Sentiment: The FDA approved TRUTAKNA for primary IgA nephropathy, making it the first and only available therapy targeting both BAFF and APRIL for this kidney disease. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy
- Positive Sentiment: Multiple reports said the approval triggered a sharp move in the stock, with investors viewing the drug approval as a key commercial catalyst for Vera Therapeutics. US FDA approves Vera’s kidney disease drug
- Positive Sentiment: Analysts responded favorably after the approval, including HC Wainwright raising its price target to $125 and Bank of America lifting its target to $70, reinforcing expectations for meaningful upside if TRUTAKNA gains traction.
- Neutral Sentiment: Wedbush also increased its price target to $43 and kept a neutral rating, suggesting the approval improved sentiment but left some analysts more cautious on valuation.
Institutional Trading of Vera Therapeutics
Several hedge funds have recently modified their holdings of VERA. Price T Rowe Associates Inc. MD lifted its position in shares of Vera Therapeutics by 49.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after acquiring an additional 1,795,537 shares during the period. Vestal Point Capital LP grew its holdings in Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after purchasing an additional 600,000 shares during the period. Integral Health Asset Management LLC increased its stake in Vera Therapeutics by 47.8% in the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after purchasing an additional 550,000 shares in the last quarter. Elmind Capital LP bought a new stake in Vera Therapeutics in the fourth quarter valued at $24,434,000. Finally, Braidwell LP bought a new stake in Vera Therapeutics in the third quarter valued at $13,738,000. Institutional investors own 99.21% of the company’s stock.
Vera Therapeutics Stock Down 1.2%
The firm’s fifty day moving average price is $36.40 and its two-hundred day moving average price is $41.16. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of -7.66 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the business posted ($0.81) earnings per share. Sell-side analysts forecast that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.
Vera Therapeutics Company Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Read More
- Five stocks we like better than Vera Therapeutics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
